$1.41
-0.07-4.73%
At Close: -
$1.35
-0.06-4.26%
After Hours: 6:51 PM EDT
15 minutes delayed
Comments
Loading...
Nektar Therapeutics
NKTRNASDAQ
Nektar Therapeutics (NASDAQ:NKTR) Stock, Analyst Ratings, Price Targets, Forecasts
Nektar Therapeutics has a consensus price target of $7.56 based on the ratings of 13 analysts. The high is $21 issued by Oppenheimer on November 5, 2021. The low is $1 issued by Jefferies on March 6, 2024. The 3 most-recent analyst ratings were released by Jefferies, Mizuho, and Jefferies on March 6, 2024, August 7, 2023, and May 10, 2023, respectively. With an average price target of $2.67 between Jefferies, Mizuho, and Jefferies, there's an implied 97.53% upside for Nektar Therapeutics from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Mizuho
Oppenheimer
Goldman Sachs
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for Nektar Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/06/2024 | Buy Now | -25.93% | Jefferies | Roger Song | $0.5 → $1 | Maintains | Hold | Get Alert |
| 11/20/2023 | Buy Now | — | JP Morgan | Jessica Fye | — | Reinstates | → Underweight | Get Alert |
| 11/09/2023 | Buy Now | — | TD Cowen | Chris Shibutani | — | Upgrade | Market Perform → Outperform | Get Alert |
| 08/07/2023 | Buy Now | 344.44% | Mizuho | Mara Goldstein | → $6 | Reiterates | → Neutral | Get Alert |
| 05/10/2023 | Buy Now | -25.93% | Jefferies | Roger Song | $1.5 → $1 | Upgrade | Underperform → Hold | Get Alert |
| 03/06/2023 | Buy Now | 122.22% | Oppenheimer | Jay Olson | $5 → $3 | Maintains | Perform | Get Alert |
| 02/27/2023 | Buy Now | 48.15% | Goldman Sachs | Chris Shibutani | $3 → $2 | Maintains | Sell | Get Alert |
| 02/24/2023 | Buy Now | 122.22% | SVB Leerink | Daina Graybosch | $5 → $3 | Maintains | Market Perform | Get Alert |
| 02/24/2023 | Buy Now | 11.11% | Jefferies | Roger Song | $3.2 → $1.5 | Downgrade | Hold → Underperform | Get Alert |
| 08/08/2022 | Buy Now | — | JP Morgan | Jessica Fye | — | Downgrade | Neutral → Underweight | Get Alert |
| 05/31/2022 | Buy Now | 196.3% | Jefferies | Roger Song | $12 → $4 | Assumes | → Hold | Get Alert |
| 04/18/2022 | Buy Now | 344.44% | Mizuho | Mara Goldstein | $8 → $6 | Maintains | Neutral | Get Alert |
| 04/18/2022 | Buy Now | 122.22% | Goldman Sachs | Chris Shibutani | → $3 | Downgrade | Neutral → Sell | Get Alert |
| 04/18/2022 | Buy Now | 344.44% | SVB Leerink | Daina Graybosch | $7 → $6 | Maintains | Market Perform | Get Alert |
| 03/16/2022 | Buy Now | 344.44% | Canaccord Genuity | Arlinda Lee | $25 → $6 | Maintains | Buy | Get Alert |
| 03/15/2022 | Buy Now | — | BTIG | Robert Hazlett | — | Downgrade | Buy → Neutral | Get Alert |
| 03/15/2022 | Buy Now | 418.52% | SVB Leerink | Daina Graybosch | $18 → $7 | Maintains | Market Perform | Get Alert |
| 03/15/2022 | Buy Now | 492.59% | Mizuho | Mara Goldstein | $35 → $8 | Downgrade | Buy → Neutral | Get Alert |
| 03/15/2022 | Buy Now | — | Cowen & Co. | Boris Peaker | — | Downgrade | Outperform → Market Perform | Get Alert |
| 03/14/2022 | Buy Now | 344.44% | B of A Securities | Greg Harrison | $18 → $6 | Downgrade | Neutral → Underperform | Get Alert |
| 03/09/2022 | Buy Now | 1455.56% | Oppenheimer | Jay Olson | → $21 | Upgrade | Perform → Outperform | Get Alert |
| 11/08/2021 | Buy Now | 1381.48% | Benchmark | Aydin Huseynov | — | Upgrade | Hold → Buy | Get Alert |
| 11/08/2021 | Buy Now | 1233.33% | SVB Leerink | Daina Graybosch | — | Maintains | Market Perform | Get Alert |
| 11/05/2021 | Buy Now | 1455.56% | Oppenheimer | — | — | Maintains | Perform | Get Alert |
| 09/10/2021 | Buy Now | 1233.33% | B of A Securities | Greg Harrison | — | Initiates | → Neutral | Get Alert |
| 08/06/2021 | Buy Now | 1307.41% | SVB Leerink | Daina Graybosch | — | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Nektar Therapeutics (NKTR) stock?
The latest price target for Nektar Therapeutics (NASDAQ:NKTR) was reported by Jefferies on March 6, 2024. The analyst firm set a price target for $1.00 expecting NKTR to fall to within 12 months (a possible -25.93% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nektar Therapeutics (NKTR)?
The latest analyst rating for Nektar Therapeutics (NASDAQ:NKTR) was provided by Jefferies, and Nektar Therapeutics maintained their hold rating.
When was the last upgrade for Nektar Therapeutics (NKTR)?
The last upgrade for Nektar Therapeutics happened on November 9, 2023 when TD Cowen raised their price target to N/A. TD Cowen previously had a market perform for Nektar Therapeutics.
When was the last downgrade for Nektar Therapeutics (NKTR)?
The last downgrade for Nektar Therapeutics happened on February 24, 2023 when Jefferies changed their price target from $3.2 to $1.5 for Nektar Therapeutics.
When is the next analyst rating going to be posted or updated for Nektar Therapeutics (NKTR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nektar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nektar Therapeutics was filed on March 6, 2024 so you should expect the next rating to be made available sometime around March 6, 2025.
Is the Analyst Rating Nektar Therapeutics (NKTR) correct?
While ratings are subjective and will change, the latest Nektar Therapeutics (NKTR) rating was a maintained with a price target of $0.50 to $1.00. The current price Nektar Therapeutics (NKTR) is trading at is $1.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.